Renato Tavares Daher

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Haifa Kathrin Al‐Ali, Martin Grießhammer, Lynda Foltz et al. · British Journal of Haematology · 2020 · 113 citations · Full text

Medicine, Hematology, Pharmacology +14

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Vikas Gupta, Martin Grießhammer, Bruno Martino et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 36 citations · Full text

Medicine, Hematology, Pharmacology +13

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, Martin Grießhammer et al. · Blood · 2014 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +4

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

Francesco Passamonti, Vikas Gupta, Bruno Martino et al. · Hematological Oncology · 2021 · 15 citations · Full text

Medicine, Hematology, Pharmacology +11

Do Low-Type Anorectal Malformations Have a Better Prognosis than the Intermediate and High Types? A Preliminary Report Using the Krickenbeck Score

P. Daher, Renato Tavares Daher, Edward Riachy et al. · European Journal of Pediatric Surgery · 2007 · 10 citations

Medicine, Surgery, Bowel Management +12